DARZALEX-SC Based Quadruplet Regimen Approved By The European Commission For Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved a new DARZALEX-SC based quadruplet regimen for patients with newly diagnosed multiple myeloma who are transplant-eligible. This approval is based on the Phase 3 PERSEUS study, which showed a significant reduction in the risk of disease progression or death.
October 23, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's DARZALEX-SC regimen has been approved by the European Commission for treating newly diagnosed multiple myeloma, showing a 58% reduction in disease progression risk.
The approval of DARZALEX-SC by the European Commission is a significant milestone for Johnson & Johnson, as it reinforces the drug's role in treating multiple myeloma. The 58% reduction in disease progression risk is a strong positive indicator for the drug's effectiveness, likely boosting investor confidence and potentially increasing JNJ's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100